MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries
19. Juni 2020 08:30 ET
|
MyoKardia, Inc.
-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 -- BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that data from...
MyoKardia to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
16. Juni 2020 08:00 ET
|
MyoKardia, Inc.
BRISBANE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the virtual...
MyoKardia Announces Pricing of Public Offering of Common Stock
12. Mai 2020 21:34 ET
|
MyoKardia, Inc.
BRISBANE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of...
MyoKardia Announces Proposed Public Offering of Common Stock
11. Mai 2020 16:02 ET
|
MyoKardia, Inc.
BRISBANE, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of...
MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
11. Mai 2020 07:30 ET
|
MyoKardia, Inc.
Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs. Placebo Mavacamten Well Tolerated; Safety Results Comparable to Placebo U.S. Regulatory...
MyoKardia Reports First Quarter 2020 Financial Results
06. Mai 2020 16:05 ET
|
MyoKardia, Inc.
BRISBANE, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the first quarter ended March 31, 2020. “Our team has continued to drive...
MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients
30. März 2020 10:30 ET
|
MyoKardia, Inc.
MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten Improvement in NT-proBNP and Troponin Levels Support Future Development in...
MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic
26. März 2020 08:30 ET
|
MyoKardia, Inc.
BRISBANE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today provided an update to the status of its clinical programs in the context of the COVID-19 (coronavirus)...
Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for Virtual Late-Breaker Presentation at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology
19. März 2020 16:45 ET
|
MyoKardia, Inc.
BRISBANE, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will be presenting data from its Phase 2 MAVERICK-HCM clinical trial during a...
MyoKardia Reports Fourth Quarter and Full Year 2019 Financial Results
27. Februar 2020 16:05 ET
|
MyoKardia, Inc.
BRISBANE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the fourth quarter and full year ended December 31, 2019. “MyoKardia...